Document is current
Any future updates will be listed below
-
Authors
Du, Siling
Zhou, Yingyue https://orcid.org/0000-0002-0923-1046
Li, Dian https://orcid.org/0000-0002-5374-7314
Lier, Julia
Cella, Marina https://orcid.org/0000-0003-1230-1313
Tada, Mari
Hamasaki, Hideomi
Wu, Junjie
Cai, Zhangying
Orthmann-Murphy, Jennifer L.
Kakita, Akiyoshi
Kipnis, Jonathan https://orcid.org/0000-0002-3714-517X
Bergner, Caroline G.
Colonna, Marco https://orcid.org/0000-0001-5222-4987
-
Funding
Funding for this research was provided by:
Cure Alzheimer's Fund
Fred and Ginger Haberle Charitable Fund at East Texas Communities Foundation
Grupa Adamed
The Global Leukodystrophy Initiative Clinical Trials Network Pilot Project Career Development Award to J.L.O-M. M. T. was supported by the Promotion of Science
Japan Agency for Medical Research and Development (JP23wm0425019)
- License Information
-
More Information
Article History
Received: 24 June 2024
Accepted: 15 May 2025
First Online: 26 June 2025
Competing interests
: M. Colonna is a member of the scientific advisory board of Vigil, NGMBio, Cartesian, Cell Signaling Technology and Halyard; receives research support from Vigil and Ono Pharmaceutical; and has patents pending on TREM2 and LILRB4. J.L.O.-M. is a site principal investigator for Vigil Neuroscience clinical trials. J.K. is cofounder of Rho Bio. The other authors declare no competing interests.
